Geron Corporation (GERN)

Oncology Corporate Profile

Stock Performance

3.0900
-0.0200

HQ Location

149 Commonwealth Drive
Menlo Park, CA 94025

Company Description

Geron Corporation develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials.

Website: http://www.geron.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
imetelstat / GRN163Ltelomerase inhibitorMultiple MyelomaII
imetelstat / GRN163Ltelomerase inhibitorMyelodysplastic Syndrome (MDS)II

View additional information on product candidates here »

Source: http://www.geron.com

Recent News Headlines

Geron Provides Update on Imetelstat Trials Being Conducted by Janssen

9/13/2016 11:19 am

(Geron) Sept 12, 2016 - Geron Corporation today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews of initial data from both trials have been completed by Janssen, and both trials are continuing in order to evaluate additional and more mature data.

Post-Mortem Cancer Study Goes National

5/13/2016 11:05 am

(Cancer Research UK) May 13, 2016 - Cancer Research UK has today announced a £4 million investment to expand the UK's first ever national study collecting blood and tissue samples from patients who have died from cancer, in a bid to shed light on what happens during the final stages of the disease.

Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting

4/20/2016 12:08 pm

(Geron) Apr 20, 2016 - Geron Corporation today announced two poster presentations of data from non-clinical studies of the telomerase inhibitor, imetelstat, at the 2016 American Association for Cancer Research (AACR) Annual Meeting held in New Orleans, Louisiana.

Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes

1/14/2016 12:01 pm

(NASDAQ) Jan 14, 2016 - Geron Corporation today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in patients with myelodysplastic syndromes (MDS).

Subsolid Lung Nodules Pose Greater Cancer Risk to Women than Men

11/24/2015 11:04 am

(RSNA) Nov 24, 2015 - Women with a certain type of lung nodule visible on lung cancer screening CT exams face a higher risk of lung cancer than men with similar nodules, according to a new study being presented next week at the annual meeting of the Radiological Society of North America (RSNA).

UH Cancer Center Clinical Trial Could Lead To New Bladder Cancer Drug

11/24/2015 11:04 am

(University of Hawaii Cancer Center at Manoa) Nov 23, 2015 - A bladder cancer drug tested in a University of Hawaii Cancer Center clinical trial gets closer to Food and Drug Administration (FDA) approval.

European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo® European Marketing Authorization Application

11/24/2015 11:04 am

(Yahoo! Finance) Nov 24, 2015 - Innovative regulatory approach enabled simultaneous review of nivolumab for two indications, expediting availability to patients.

FDA Drug Safety Communication: FDA Warns That Cancer Drug Docetaxel May Cause Symptoms Of Alcohol Intoxication After Treatment

11/24/2015 11:04 am

(FDA.gov) Updated Nov 23, 2015 - The U.S. Food and Drug Administration (FDA) is warning that the intravenous chemotherapy drug docetaxel contains ethanol, also known as alcohol, which may cause patients to experience intoxication or feel drunk during and after treatment.

ASTRO Launches Template To Help Radiation Oncologists Guide Cancer Survivors Through Ongoing Care

11/24/2015 11:04 am

(ASTRO) Nov 23, 2015 - A new template published by the American Society for Radiation Oncology (ASTRO) standardizes and streamlines the creation of patient-focused plans for long-term cancer survivor care following radiation therapy (RT).

Report Examines Cancer Surgeries in California Hospitals

11/24/2015 11:04 am

(California Healthline) Nov 23, 2015 - A report released last week looked at 11 types of cancer surgeries and reviewed how often they were performed at hospitals across California. In general, hospitals performing a higher volume of some of those kinds of surgeries have better outcomes, so patients could potentially use the new information to find hospitals that do more of those surgeries.

Medidata’s Risk-Based Monitoring Solution Selected by Infinity Pharmaceuticals to Advance Oncology Research

11/24/2015 11:04 am

(Investor’s Business Daily) Nov 23, 2015 - Increased adoption of the Medidata Clinical Cloud® enables safer, faster and more insightful clinical trials.

Two New Multiple Myeloma Drugs Win Approval as Pipeline Builds Hope for Blood Cancer Patients

11/24/2015 11:04 am

(LLS.org) Nov 23, 2015 - The Leukemia & Lymphoma Society (LLS) applauds the FDA's recent approval of two new drugs -- daratumumab and ixazomib -- to treat patients with relapsed multiple myeloma. These therapies are the latest in a growing arsenal to fight this blood cancer that impacts nearly 100,000 patients in the U.S.

FDA Approves Expanded Use Of Bristol-Myers' Skin Cancer Drug

11/24/2015 11:04 am

(Reuters) Nov 24, 2015 - Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved the expanded use of its cancer drug, Opdivo, to treat an additional form of advanced skin cancer.

Genmab Announces Ofatumumab Phase III Study in Follicular Lymphoma to be Stopped Following Planned Interim Analysis

11/24/2015 07:00 am

(TheStreet) Nov 23, 2015 - Phase III study of ofatumumab in follicular lymphoma will be stopped early; planned interim analysis by an Independent Data Monitoring Committee showed that the study was unlikely to show superiority of ofatumumab if completed; no new safety signals for ofatumumab were identified.

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival in Advanced Renal Cell Carcinoma vs. a Standard of Care, in Patients Who Have Received Prior Anti-Angiogenic Therapy

11/24/2015 07:00 am

(BMS) Nov 23, 2015 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma

11/24/2015 07:00 am

(BMS) Nov 24, 2015 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, as a single agent for the treatment of patients with BRAF V600 wild-type (WT) unresectable or metastatic melanoma.

Administration Is Seeking Ways to Keep Prescription Drugs Affordable

11/23/2015 12:05 pm

(New York Times) Nov 20, 2015 - The Obama administration on Friday hosted a forum to address ways in which the government could help protect against high pharmaceutical costs.

CTI BioPharma Initiates Rolling Submission of U.S. New Drug Application for Pacritinib for the Treatment of Patients with Myelofibrosis

11/23/2015 12:05 pm

(TheStreet) Nov 23, 2015- CTI BioPharma Corp. announced the initiation of its rolling new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R.

Data Doesn't Support Nod For Biomarin's Muscle-Wasting Drug: FDA Staff

11/23/2015 12:04 pm

(FoxNews/Reuters) Nov 20, 2015 - U.S. Food and Drug Administration staff reviewers said clinical data to date did not merit approving BioMarin Pharmaceutical Inc's muscle-wasting disorder drug.

Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis

9/16/2015 11:36 am

(CNNMoney) Sept 16, 2015 - Geron Corporation today announced the dosing of the first patient in a Phase 2 clinical trial to evaluate imetelstat in patients with myelofibrosis (MF).

Cancer Nonprofit Investigated by Tennessee Secretary of State’s Office

7/8/2015 11:04 am

(Wall Street Journal) July 7, 2015 - The Tennessee secretary of state’s office is investigating a cancer nonprofit with family ties to four other charities that were sued in May by the federal government on allegations they bilked donors of $187 million, according to a person familiar with the matter.

Geron Corp Announces Receipt of FDA Orphan Drug Designation for Imetelstat as Myelofibrosis Treatment

6/15/2015 12:25 pm

(StreetInsider) June 15, 2015 - On June 11, 2015, the United States Food and Drug Administration (the “FDA”) granted orphan-drug designation to imetelstat for the treatment of myelofibrosis.

Number of Childhood Cancer Survivors Increasing, Most Have Morbidities

4/1/2015 12:01 pm

(AACR) Apr 1, 2015 - The prevalence of childhood cancer survivors is estimated to have increased, and the majority of those who have survived five or more years beyond diagnosis may have at least one chronic health condition.

In Its Bumpy Second Life, Geron Signs Top Drug Over to J&J

11/14/2014 11:44 am

(Xconomy San Francisco) Nov 13, 2014 - As we saw this week with Dendreon, pioneers in the biomedical industry can end up with arrows in their back, bleeding to death. Geron has avoided that fate.

Geron Could Get $935M in Blood Disorder Drug Deal

11/14/2014 07:47 am

(BloombergBusinessweek/Associated Press) Nov 13, 2014 - Geron Corp. said Thursday it could get more than $900 million from a deal to develop its blood disorder drug imetelstat with a unit of Johnson & Johnson.

After A Long Year, An Update on Geron's Myelofibrosis Drug Is Disclosed

11/6/2014 11:57 am

(TheStreet) Nov 6, 2014 - Updated results from a small study of Geron's experimental myelofibrosis drug imetelstat disclosed Thursday yielded a remission rate of 21%, essentially unchanged from results presented one year ago, with significant side effects.

Geron Announces Removal of Full Clinical Hold on Imetelstat IND

11/3/2014 07:06 am

(NASDAQ) Nov 3, 2014 - Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on Geron's investigational new drug (IND) application for imetelstat.

Discussing Healthcare Reform at #ACCC2014

10/24/2014 06:05 am

(ACCCBuzz) Oct 23, 2014 - ACCC’s recent 31st National Oncology Conference featured 45-minute “think tanks,” supported by a grant from Genentech, on four hot topics in oncology.

FDA Lifts Partial Hold on Study Testing Geron's Only Drug

6/12/2014 11:31 am

(Reuters) June 12, 2014 - Geron Corp said the U.S. Food and Drug Administration had lifted a partial clinical hold on a study testing its sole drug as a treatment for myelofibrosis, a rare form of blood cancer, sending the company's shares soaring in morning trading.

Geron Reports Removal of Partial Clinical Hold on Myelofibrosis IST

6/12/2014 06:48 am

(MarketWatch) June 12, 2014 - Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST).

FDA Lifts Partial Hold on Study Testing Geron's Only Drug

6/12/2014 06:03 am

(Reuters) June 12, 2014 - Geron Corp said the U.S. Food and Drug Administration had lifted a partial clinical hold on a study testing its sole drug as a treatment for myelofibrosis, a rare form of blood cancer, sending the company's shares soaring in morning trading.

Geron Reports Removal of Partial Clinical Hold on Myelofibrosis IST

6/12/2014 01:04 am

(MarketWatch) June 12, 2014 - Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST).

FDA Approves Biogen Hemophilia Drug

6/9/2014 07:03 am

(Boston Globe) June 6, 2014 - Two months after US regulators approved the first new hemophilia treatment in 17 years, its maker, Biogen Idec Inc., got the okay Friday to market a similarly long-acting drug that controls and prevents bleeding in adults and children with the most common form of the disease.

Geron Reports Myelofibrosis IST Placed on Partial Clinical Hold

3/20/2014 11:24 am

(Geron) Mar 20, 2014 - Geron Corporation announced today that patients currently enrolled in the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST) who are deriving clinical benefit may continue imetelstat treatment under a partial clinical hold placed by the U.S. Food and Drug Administration (FDA).

Geron Reports Myelofibrosis IST Placed on Partial Clinical Hold

3/20/2014 11:02 am

(Geron) Mar 20, 2014 - Geron Corporation announced today that patients currently enrolled in the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST) who are deriving clinical benefit may continue imetelstat treatment under a partial clinical hold placed by the U.S. Food and Drug Administration (FDA).

Geron Says FDA Halts Testing of Lead Drug, Shares Slump

3/12/2014 11:35 am

(Reuters) Mar 12, 2014 - Geron Corp said the U.S. Food and Drug Administration ordered to halt trials of its only remaining drug over concerns about liver damage, wiping out about two-thirds of the company's value.

Geron Says FDA Halts Testing of Lead Drug, Shares Slump

3/12/2014 11:03 am

(Reuters) Mar 12, 2014 - Geron Corp said the U.S. Food and Drug Administration ordered to halt trials of its only remaining drug over concerns about liver damage, wiping out about two-thirds of the company's value.

Geron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple Myeloma

3/12/2014 06:44 am

(MarketWatch) Mar 12, 2014 - Geron Corporation announced today that the company has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trials.

Geron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple Myeloma

3/12/2014 06:04 am

(MarketWatch) Mar 12, 2014 - Geron Corporation announced today that the company has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trials.